Abstract
During the past several years, advances in the treatment of non-small cell lung cancer (NSCLC) have predominantly involved the development of therapies directed at molecular targets. Treatment based on histology and molecular characterization has become a guideline of care in the era of targeted therapy. Among numerous driver genes of NSCLC, epidermal growth factor receptor(EGFR) gene is one molecular target concerning with most researches, abundant evidences and thorough understandings. Epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI) has been widely used in the treatment of NSCLC haboring EGFR mutation. This review provides an overview of current EGFR gene related targeted therapies in NSCLC. Key words: Non-small cell lung cancer; Pulmonary adenocarcinoma; Epidermal growth factor receptor; Molecular targeted therapy
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
